Free Trial
→ Here’s Why Trump Won’t End The Iran War (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
+200.0%		$0.00
$0.00
▼
$0.00
$1K-1.52689 shs100 shs
MannKind Corporation stock logo
MNKD
MannKind
$3.02
-1.0%		$3.79
$2.23
▼
$6.51
$971.05M1.095.27 million shs7.93 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%0.00%0.00%0.00%-50.00%
MannKind Corporation stock logo
MNKD
MannKind
-2.56%-17.79%-18.67%-25.43%-40.20%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
+200.0%		$0.00
$0.00
▼
$0.00
$1K-1.52689 shs100 shs
MannKind Corporation stock logo
MNKD
MannKind
$3.02
-1.0%		$3.79
$2.23
▼
$6.51
$971.05M1.095.27 million shs7.93 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%0.00%0.00%0.00%-50.00%
MannKind Corporation stock logo
MNKD
MannKind
-2.56%-17.79%-18.67%-25.43%-40.20%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00
N/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
2.60
Moderate Buy$7.84159.73% Upside

Current Analyst Ratings Breakdown

Latest MNKD and CALA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/7/2026
MannKind Corporation stock logo
MNKD
MannKind
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$6.00 ➝ $5.00
10/5/2026
MannKind Corporation stock logo
MNKD
MannKind
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong Sell ➝ Hold
10/2/2026
MannKind Corporation stock logo
MNKD
MannKind
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D)
9/11/2026
MannKind Corporation stock logo
MNKD
MannKind
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight$8.00
9/3/2026
MannKind Corporation stock logo
MNKD
MannKind
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold ➝ Strong Sell
8/6/2026
MannKind Corporation stock logo
MNKD
MannKind
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOverweight$14.00 ➝ $13.00
8/5/2026
MannKind Corporation stock logo
MNKD
MannKind
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong Sell ➝ Hold
7/30/2026
MannKind Corporation stock logo
MNKD
MannKind
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$11.00 ➝ $14.00
7/23/2026
MannKind Corporation stock logo
MNKD
MannKind
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
$348.97M2.78$0.06 per share50.58($0.17) per share-17.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$39.65MN/AN/AN/AN/AN/AN/AN/A11/17/2026 (Estimated)
MannKind Corporation stock logo
MNKD
MannKind
$5.86M-$0.13N/A302.00N/A-11.08%N/A-6.31%11/4/2026 (Estimated)

Latest MNKD and CALA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
MannKind Corporation stock logo
MNKD
MannKind
-$0.0575N/AN/AN/A$109.49 millionN/A
8/5/2026Q2 2026
MannKind Corporation stock logo
MNKD
MannKind
-$0.0075-$0.01-$0.0025-$0.06$108.08 million$109.37 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/A
1.72
1.41

Institutional Ownership

CompanyInstitutional Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/A
MannKind Corporation stock logo
MNKD
MannKind
49.55%

Insider Ownership

CompanyInsider Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
6.60%
MannKind Corporation stock logo
MNKD
MannKind
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
603.86 million4.55 millionNot Optionable
MannKind Corporation stock logo
MNKD
MannKind
592321.54 million313.18 millionOptionable

Recent News About These Companies

MannKind to Participate in the Chardan Healthcare Conference
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/14/3381121/29517/en/mannkind-to-participate-in-the-chardan-healthcare-conference.html
MannKind Corporation (NASDAQ:MNKD) Stock Has Average Target Price of $7.84 According to Brokerages
October 12 at 2:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109238
MannKind Corporation (NASDAQ:MNKD) Stock Now Rated "Moderate Buy" by Sell-Side Analysts
October 12 at 2:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-mannkind-corporation-nasdaq-mnkd-stock-now-rated-moderate-buy-by-sell-side-analysts-2026-10-12/
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the ...
October 10, 2026  |  enidnews.comE
Truist Financial Keeps Their Buy Rating on MannKind (MNKD)
October 10, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MNKD/pressreleases/5523928/truist-financial-keeps-their-buy-rating-on-mannkind-mnkd/
Mannkind Corporation Presents New Clinical Data Related to Furoscix Readyflow At Heart Failure Society of America Annual Scientific Meeting
October 10, 2026  |  marketscreener.comM
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
October 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/10/3378422/29517/en/mannkind-data-at-hfsa-2026-highlights-new-evidence-supporting-furoscix-readyflow-for-the-outpatient-management-of-edema-in-heart-failure-hf-and-chronic-kidney-disease-ckd.html
MannKind Presents New Data Showing Furoscix ReadyFlow Delivers IV-Equivalent Diuresis Across Injection Sites at HFSA 2026
October 9, 2026  |  quiverquant.comQ
MannKind (NASDAQ:MNKD) Shares Down 5.1% - What's Next?
October 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-mannkind-nasdaq-mnkd-shares-down-51-whats-next-2026-10-09/
Truist Financial Has Lowered Expectations for MannKind (NASDAQ:MNKD) Stock Price
October 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31101245
MannKind (NASDAQ:MNKD) Stock Price Target Lowered at Truist Financial
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-mannkind-nasdaq-mnkd-stock-price-target-lowered-at-truist-financial-2026-10-07/
MannKind (NASDAQ:MNKD) Stock Rating Raised to Hold at Zacks Research
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31096199
Zacks Research Upgrades MannKind (NASDAQ:MNKD) to "Hold"
October 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-zacks-research-upgrades-mannkind-nasdaq-mnkd-to-hold-2026-10-07/
MannKind stock weighs 43 percent revenue growth against losses
October 5, 2026  |  ad-hoc-news.deA
MannKind stock fell 3.8 percent as analysts kept a positive view
October 4, 2026  |  ad-hoc-news.deA
MannKind (NASDAQ:MNKD) Shares Down 4.7% - What's Next?
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-mannkind-nasdaq-mnkd-shares-down-47-whats-next-2026-10-02/
MannKind stock adds an inhaled GLP-1 licensing deal
October 1, 2026  |  ad-hoc-news.deA
MannKind (NASDAQ:MNKD) Shares Climb 6.3% - Here's Why
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-mannkind-nasdaq-mnkd-shares-climb-63-heres-why-2026-09-30/
Steven Binder vende azioni MannKind (MNKD) per $128.477
September 29, 2026  |  it.investing.comhttps://it.investing.com/news/insider-trading-news/steven-binder-vende-azioni-mannkind-mnkd-per-128477-93CH-3565783
MannKind (NASDAQ:MNKD) Director Sells $128,477.79 in Stock
September 29, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-mnkd-insider-buying-and-selling-2026-09-29/
Insider Selling: MannKind (NASDAQ:MNKD) Director Sells $128,477.79 in Stock
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-mannkind-nasdaq-mnkd-director-sells-12847779-in-stock-2026-09-28/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Calithera Biosciences stock logo

Calithera Biosciences NASDAQ:CALA

$0.0003 +0.00 (+200.00%)
As of 09:30 AM Eastern

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

MannKind stock logo

MannKind NASDAQ:MNKD

$3.02 -0.03 (-0.98%)
Closing price 04:00 PM Eastern
Extended Trading
$3.08 +0.06 (+1.82%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas